

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
3 September 2009 (03.09.2009)(10) International Publication Number
WO 2009/106819 A2(51) International Patent Classification:
C07K 14/35 (2006.01) *A61K 38/16* (2006.01)(74) Agent: **WAINWRIGHT, Jane**; Potter Clarkson LLP,
Park View House, 58 The Ropewalk, Nottingham NG1
5DD (GB).(21) International Application Number:
PCT/GB2009/000522

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(22) International Filing Date:
25 February 2009 (25.02.2009)(71) Applicant (for all designated States except US):
HELPERBY THERAPEUTICS LIMITED [GB/GB];
20/24 Park Street, Selby, North Yorks YO8 4PW (GB).
(72) Inventors; and
(75) Inventors/Applicants (for US only): **COATES, Anthony, Robert, Milnes** [GB/GB]; Helperby Therapeutics Limited, Earlsfield Business Centre (Unit 18), 9 Lydden Road, London SW18 4LT (GB). **RIFFO-VASQUEZ, Yanira** [CL/GB]; Helperby Therapeutics Limited, Earlsfield Business Centre (Unit 18), 9 Lydden Road, London SW18 4LT (GB). **TORMAY, Peter** [DE/GB]; Helperby Therapeutics Limited, Earlsfield Business Centre (Unit 18), 9 Lydden Road, London SW18 4LT (GB).**Published:**

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: BIOLOGICAL MATERIALS AND USES THEREOF

Figure 1

(57) Abstract: The present invention concerns a peptide molecule or a nucleic acid molecule, for use in medicine and, in particular, for use in preventing or treating a non- cancerous condition or relieving pain in a patient. The invention also relates to a pharmaceutical composition comprising the peptide or nucleic acid molecule of the invention and methods of treatment thereof.

BIOLOGICAL MATERIALS AND USES THEREOF

The present invention relates to polypeptides deriving from chaperonin 60.1 and their uses in the treatment of disease and as pain relief agents.

5

Heat shock polypeptides are a family of molecules found in all organisms, whose function is to aid the biological processing and stability of biological molecules (Zugel & Kauffman (1999) *Role of heat shock polypeptides in protection from and pathogenesis of infectious diseases*. Clin. Microbiol. Rev. (12)1: 19-39; Ranford et al. (2000) *Chaperonins are cell signalling polypeptides: - the unfolding biology of molecular chaperones*. Exp. Rev. Mol. Med., 15 September, www.ermn.cbcu.cam.ac.uk/00002015h.htm).

10

Heat shock polypeptides are located in every cellular compartment, and possess the ability to interact with a wide range of biological molecules. In particular, the heat shock polypeptides aid and influence polypeptide folding and polypeptide translocation at any time from assembly through to disassembly of the polypeptide and any complexes thereof. The helper nature of the heat shock polypeptides has led to them to also being known as molecular chaperones (Laskey et al. (1978) *Nucleosomes are assembled by an acidic polypeptide, which binds histones and transfers them to DNA*. Nature (275): 416-420).

15

Heat shock polypeptides are synthesised by cells in response to environmental stress, which includes, but is not limited to temperature changes (both increases and decreases), and pathophysiological signals such as cytokines. In response to the environmental stress, heat shock polypeptides use their ability to process other polypeptides to protect such polypeptides from any denaturation that may occur due to the presence of the stress. This mechanism also serves to protect cells which contain the protein.

20

Chaperonin polypeptides are a subgroup of heat shock polypeptides whose role in polypeptide folding is well known. There are two families of chaperonin polypeptide, the chaperonin 60 (approximately 60 kDa) and chaperonin 10 (approximately 10 kDa) families (Ranford, 2000). The best characterised chaperonins are those derived from *E. coli*, from which the characteristic structure of chaperonin 60 and chaperonin 10 has been established. The chaperonin

25

30

35

complexes of most other organisms also substantially conform to this characteristic structure.

The characteristic structure of chaperonins is a complex formed from two
5 heptamer rings (composed of seven chaperonin 60 monomers) which face one another and are capped by a heptamer ring composed of chaperonin 10 monomers.

Conventionally, chaperonins assist polypeptide folding when the target
10 polypeptide enters the central core of the ringed heptamers, and on the subsequent release of energy from ATP the target polypeptide is released from the central core by a conformational change in the chaperonin structure (Ranson *et al.* (1998) *Review Article: Chaperones. Biochem. J* (333): 233-242).

15 *Mycobacterium tuberculosis* (*M. tuberculosis*) produces Chaperonin 60.1 (cpn 60.1), a polypeptide that is named based on its amino acid sequence identity to other known chaperonins. Further *M. tuberculosis* chaperonin polypeptides are chaperonin 10 (cpn 10) and chaperonin 60.2 (cpn 60.2). Chaperonin 60.2 exhibits 59.6% amino acid sequence identity and 65.6% nucleic acid sequence identity to
20 cpn 60.1.

The present invention relates to the use of fragments of chaperonin 60.1 or functionally equivalent molecules from *Mycobacterium tuberculosis* or related prokaryotes in the prevention and/or treatment of both cancerous and non-
25 cancerous conditions. Examples of non-cancerous conditions include autoimmune disorders, osteoporosis, allergic disorders or conditions of immunoactivation, particularly asthma, and/or conditions typified by a T helper lymphocyte 2 (Th2)-type immune response and/or conditions associated with eosinophilia and methods of stimulating the production of immune response mediators, e.g. cytokines, in vitro or in vivo.
30

Autoimmunity reflects the loss of tolerance to "self" resulting in inappropriate destruction of normal cells or tissue. In many conditions, autoantibodies are found, but may reflect an effect rather than cause of a disease. In some diseases
35 however autoantibodies are the first, major, or only detectable abnormality. One class of molecules which is implicated in this respect are the chaperonins which

are highly immunogenic. Chaperonins belong to a group of proteins called molecular chaperones which bind non-native proteins and assist them, in an ATP-dependent catalytic process, to fold into the correct three-dimensional form required for a functional protein.

5

Chaperonins are believed to stimulate the immune system at many levels simultaneously, including monocytes, macrophages, fibroblast-like cells, perhaps other types of cells, and T cells. The immune defences in mammals may be divided into the "innate" and "adaptive" defences. Those which are already in place, such as phagocytes, natural killer cells and complement are considered innate. On challenge, adaptive immunity is activated in the form of B and T lymphocytes. Chaperonins are known to act directly on the innate defence mechanisms, particularly on phagocytes. They also stimulate a powerful adaptive immune response, namely the production of antibody and the stimulation of T lymphocytes which in some cases may be protective. Notably they induce cytokine secretion which is thought to be important for host defences. In some cases however it is believed that the presence of chaperonins may be damaging to the host.

20 Chaperonins' role in autoimmune disease is controversial. Although infection/immunity with chaperonin-containing organisms is universal, and healthy people have T cell responses to self-chaperonins, including the production of chaperonin-specific antibodies, classical autoimmune disease is quite uncommon. So the presence of immune reactions to chaperonins may be incidental and unimportant.

25 The theory of molecular mimicry however suggests the involvement of chaperonins in autoimmune disease and is based on the high level of amino acid sequence conservation between chaperonins of microbial and mammalian origin. The theory proposes that during infection with a wide range of microbes, chaperonin epitopes that are shared between microbes and mammals stimulate T lymphocytes. According to this theory a high level of chaperonin presentation of shared chaperonin epitopes breaks tolerance to self-chaperonins and autoimmune disease develops.

35

Chaperonins obtained from tumours have been found to result in necrotic effects on those tumours. It is suggested that this may be achieved through enhancing immunological recognition of tumour antigens although the mechanism of this is not known. It therefore appears that chaperonins induce protective adaptive
5 immunity against bacterial infection and cancer.

- Allergic reactions, such as asthma, concern proportionally inappropriate or misdirected immune responses. The prevalence of asthma for example is increasing and effective therapies for treating all cases have not yet been found.
10 Current treatment often uses immunosuppressive glucocorticosteroids, beta agonists, cromoglycate, leukotriene modifiers etc. which have numerous side-effects.
- In such allergic reactions, high IgE levels occur and T helper lymphocyte-2 (Th2)
15 immune responses predominate over Th1 responses resulting in an inflammatory response. Th1 responses are thought to be mainly protective against microbial infection and are promoted by cytokines, particularly interleukin-12 (IL-12), IL-2 and interferon- γ . In contrast, Th2 responses, in the appropriate genetic background, are associated with harmful allergic tissue damage.
20
- However, it has been suggested that in other conditions such as autoimmune disorders, e.g. adjuvant arthritis, overactive Th1 responses are causal of the disorder. Conversion of Th1 to Th2 or Th2 to Th1 responses may therefore have utility in treating the above described disorders.
25
- Whilst it has been known that bacteria such as *L. monocytogenes*, *M. bovis* and *M. tuberculosis* can convert Th2 to Th1 responses, the molecules which is(are) responsible for this conversion have not been identified.
30 Suggestions in the art have however implicated a heat shock protein, hsp65, from *M. leprae* which is able to induce Th1 responses (Lowrie et al., 1999, Nature, 400, p269-271; Bonato et al., 1998, Infect. Immun., 66, p169-175). The homologue, hsp65 from *M. tuberculosis*, has the ability to stimulate human monocytes to synthesize pro-inflammatory cytokines and activate monocytes and
35 human vascular endothelial cells (Friedland et al., 1993, Clin. Exp. Immunol., 91,

p5862; Peetermans et al., 1995, Infect. Immun., 63, p3454-3458; Verdegaal, et al., 1996, J. Immunol., 157, p369-376).

The present invention also relates to the use of fragments of chaperonin 60.1 or
5 functionally equivalent molecules from *Mycobacterium tuberculosis* or related prokaryotes in the relief of pain.

Pain relief is usually achieved by oral or parenteral medication. Effective pain relief can be achieved in most cases with widely known pain relief drugs such as
10 paracetamol, aspirin and other non-steroidal anti-inflammatory drugs (NSAIDS) such as ibuprofen, and cylooxygenase-2-selective inhibitors (CSIs). Narcotic analgesics act on specific receptors in the Central Nervous System (CNS). Codeine and dihydrocodeine are moderately potent narcotic analgesics and have a low potential for addiction. Other more potent narcotic analgesics, such as
15 morphine and methadone can be used to control severe pain.

A variety of problems exist with presently known pain relief agents. The drugs are relatively short acting and analgesia lasts for only a few hours. Repeated doses of the drug are usually necessary to control the pain. Sub-optimal pain relief is
20 another common problem, leading to the patient increasing the dose, or changing medication. In the case of NSAIDS, unpleasant gastrointestinal side-effects such as dyspepsia and ulcers are common, and about two-thirds of users change brands of NSAIDS at least once because of adverse effects and poor efficacy (Steinfeld S and Bjorke PA. Results from a patient survey to assess
25 gastrointestinal burden of non-steroidal anti-inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with rofecoxib. **Rheumatology (Oxford)** 2002, 41(S1), 23-27.). In addition, NSAIDs and CSIs can give rise to cardiovascular complications (Hillis W S, (2000) Areas of emerging interest in analgesia: cardiovascular complications. **Am. J. Ther.** 9 (3)
30 259-69). Aspirin can cause Reye Syndrome in a small proportion of children, and thus aspirin is not available for use in children. Paracetamol has to be used with caution since, an overdose, is hepatotoxic (Cranswick, N., Coghlan D. Paracetamol efficacy and safety in children: the first 40 years (2000) **Am. J. Ther.** 7(2) 135-41). Narcotic analgesics have a variety of side-effects including
35 drowsiness, constipation, nausea, headache and vertigo. Repeated

administration of potent narcotic analgesics such as morphine can cause addiction.

An advantage of chaperonins as pain relief agents over current pain relief drugs

5 is that they may have fewer adverse side-effects. It has been estimated that two billion people carry *M. tuberculosis* without developing Tuberculosis. Carriage of *M. tuberculosis* has not been associated with the side effects which are seen with commonly known pain-relief medication such as gastro-intestinal side-effects, cardiovascular complications, hepatotoxicity, Reye Syndrome or addiction.

10

A further advantage over previously known pain relief agents is that, the analgesic affect of chaperonins will last longer.

15 Against this background, the present inventors have now surprisingly identified peptides and polypeptide fragments of the chaperonin protein Chaperonin 60.1 (also referred to herein as Cpn60.1) of *Mycobacterium tuberculosis* that are capable of treating both cancerous and no-cancerous conditions and also of providing pain relief *in vivo* and *in vitro*.

20 Thus, in a first aspect, the invention provides an isolated or recombinant peptide molecule comprising or consisting of a polypeptide sequence selected from the group:

- (i) MSKLIEYDETARRAMEVGMDKLADTVRVT;
 - (ii) LGPRGRHVVLAFAFGGPTVTN;
 - (iii) DGVTVAREIELEDPFEDLGAQLVKSVATKTNDV;
 - (iv) AGDGTTTATILAQALIKGGLRLVAAGVN;
 - (v) PIALGVGIGKAADAVSEALLASATP;
 - (vi) EEGIVPGGGASLIHQARKALTELRASL;
 - (vii) TGDEVLGVDVFSEALAAPLFWIAANAGL;
 - (viii) DGSVVVNVKSELPAHGGLNVNTLSYGDLAAD;
 - (ix) GVIDPVKVTRSAVLNASSVARMVLTTETVWW;
 - (x) LTTETVVVDKPAKAEDHDHHHGHAH;
- 35 (xi) a polypeptide sequence which has more than 66% or 70% or 75% or 80% or 85% or 90% or 95% identity to a polypeptide sequence

defined in any of (i) to (x) and has a function equivalent to a polypeptide sequence defined in any of (i) to (x); and

- 5 (xii) a fragment of a polypeptide sequence defined in any of (i) to (xi)
which has a function equivalent to a polypeptide sequence defined
in any of (i) to (xi).

By "polypeptide" we also include peptides, proteins and peptidomimetic compounds. The term "peptidomimetic" refers to a compound that mimics the
10 conformation and desirable features of a particular peptide as a therapeutic agent, but that avoids the undesirable features.

By "a function equivalent to a polypeptide sequence defined in any of (i) to (x)" we include any peptide, polypeptide and/or fragment thereof which possesses a
15 functional activity identical or substantially similar to any function displayed by or attributed to the defined polypeptide sequence. For example, the polypeptide sequences defined in (i) to (x) may exhibit anti-inflammatory properties (as exemplified in the accompanying examples) permitting their use in the prevention and/or treatment of a non-cancerous condition, or in the relief of pain.

20 Functional equivalence can be measured using, for example, methods described in the accompanying examples (for example by measuring paw latency on a heated plate; or measuring the release of inflammatory cytokines *in vivo* or *in vitro*).

25 The terms "polypeptide" or "peptide" or "amino acid sequence" refer to an oligopeptide, peptide, polypeptide or protein sequence or fragment thereof and to naturally occurring or synthetic molecules. A polypeptide "fragment," "portion," or "segment" is a stretch of amino acid residues of at least about 5 amino acids,
30 preferably at least about 7 amino acids, more preferably at least about 9 amino acids and most preferably at least about 17 or more amino acids. The peptide preferably is not greater than about 200 amino acids, more preferably less than 150 amino acids and most preferably less than 100 amino acids. Preferably the peptide is from about 5 to about 200 amino acids. To be active, any polypeptide
35 must have sufficient length to display biological and/or immunological activity.

The term "naturally occurring polypeptide" refers to polypeptides produced by cells that have not been genetically engineered and specifically contemplates various polypeptides arising from post-translational modifications of the polypeptide including, but not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation.

5 The term "derivative" refers to polypeptides chemically modified by such techniques as ubiquitination, labeling (e.g., with radionuclides or various enzymes), covalent polymer attachment such as pegylation (derivatization with 10 polyethylene glycol) and insertion or substitution by chemical synthesis of amino acids such as ornithine, which do not normally occur in human proteins.

15 The term "variant" (or "analog") refers to any polypeptide differing from naturally occurring polypeptides by amino acid insertions, deletions, and substitutions, created using, e.g., recombinant DNA techniques. Guidance in determining which amino acid residues may be replaced, added or deleted without abolishing activities of interest, may be found by comparing the sequence of the particular 20 polypeptide with that of homologous peptides and minimizing the number of amino acid sequence changes made in regions of high homology (conserved regions) or by replacing amino acids with consensus sequence.

25 Alternatively, recombinant variants encoding these same or similar polypeptides may be synthesized or selected by making use of the "redundancy" in the genetic code. Various codon substitutions, such as the silent changes which produce various restriction sites, may be introduced to optimize cloning into a plasmid or viral vector or expression in a particular prokaryotic or eukaryotic system. Mutations in the polynucleotide sequence may be reflected in the polypeptide or domains of other peptides added to the polypeptide to modify the properties of 30 any part of the polypeptide, to change characteristics such as ligand-binding affinities, interchain affinities, or degradation/turnover rate.

35 Preferably, amino acid "substitutions" are the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, i.e., conservative amino acid replacements. "Conservative" amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues

involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include 5 arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid. "Insertions" or "deletions" are preferably in the range of about 1 to 20 amino acids, more preferably 1 to 10 amino acids. The variation allowed may be experimentally determined by systematically 10 making insertions, deletions, or substitutions of amino acids in a polypeptide molecule using recombinant DNA techniques and assaying the resulting recombinant variants for activity.

Alternatively, where alteration of function is desired, insertions, deletions or non-conservative alterations can be engineered to produce altered polypeptides. 15 Such alterations can, for example, alter one or more of the biological functions or biochemical characteristics of the polypeptides of the invention. For example, such alterations may change polypeptide characteristics such as ligand-binding affinities, interchain affinities, or degradation/turnover rate. Further, such alterations can be selected so as to generate polypeptides that are better suited 20 for expression, scale up and the like in the host cells chosen for expression. For example, cysteine residues can be deleted or substituted with another amino acid residue in order to eliminate disulfide bridges.

Fragments of the proteins of the present invention which are capable of exhibiting 25 biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H. U. Saragovi, *et al.*, *Bio/Technology* 10, 773-778 (1992) and in R. S. McDowell, *et al.*, *J. Amer. Chem. Soc.* 114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may 30 be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites.

The invention further provides an isolated or recombinant nucleic acid molecule comprising or consisting of a polynucleotide sequence selected from the group:

(a) a polynucleotide sequence which encodes a polypeptide sequence selected from the group consisting of:

- 5 (i) MSKLIEYDETARRAMEVGMDKLADTVRVT;
 (ii) LGPRGRHVVLAQAFGGPTVTN;
 (iii) DGTVAREIELEDPFEDLGAQLVKSATKTNDV;
 (iv) AGDGTTTATILAQALIKGGLRLVAAGVN;
 (v) PIALGVGIGKAADAVSEALLASATP;
 (vi) EEGIVPGGGASLIHQARKALTELRASL;
10 (vii) TGDEVLGVDFVFSEALAAPLFWIAANAGL;
 (viii) DGSVVVNKVSELPAGHGLNVNTLSYGDLAAD;
 (ix) GVIDPVKVTRSAVLNASSVARMVLTETVVV;
 (x) LTETVVVDKPAKAEDHDHHHGHAH;

- 15 (b) a polynucleotide sequence which has more than 66% or 70% or 75% or 80% or 85% or 90% or 95% identity to a polynucleotide sequence defined in (a); or a polynucleotide sequence which hybridizes to a polynucleotide sequence defined in (a) under conditions of 2xSSC, 65°C which encodes a polypeptide sequence having a function equivalent to a polypeptide sequence defined in any of (i) to (x); and
20 (c) a fragment of a polynucleotide sequence defined in (a) or (b) which encodes a polypeptide sequence having a function equivalent to a polypeptide sequence defined in any of (i) to (x).
25

The terms "nucleotide sequence" or "nucleic acid" or "polynucleotide" or "oligonucleotide" are used interchangeably and refer to a heteropolymer of nucleotides or the sequence of these nucleotides. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA) or to any DNA-like or RNA-like material. In the sequences herein A is adenine, C is cytosine, T is thymine, G is guanine and N is A, C, G or T (U). It is contemplated that where the polynucleotide is RNA, the T (thymine) in the sequences provided herein is substituted with U (uracil). Generally, nucleic acid segments provided by this invention may be assembled from fragments of

the genome and short oligonucleotide linkers, or from a series of oligonucleotides, or from individual nucleotides, to provide a synthetic nucleic acid which is capable of being expressed in a recombinant transcriptional unit comprising regulatory elements derived from a microbial or viral operon, or a eukaryotic gene.

5

The polynucleotides of the invention include naturally occurring or wholly or partially synthetic DNA, e.g., cDNA and genomic DNA, and RNA, e.g., mRNA. The polynucleotides may include all of the coding region of the cDNA or may represent a portion of the coding region of the cDNA.

10

The present invention also provides genes corresponding to the cDNA sequences disclosed herein. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. Further 5' and 3' sequence can be obtained using methods known in the art. For example, full length cDNA or genomic DNA that corresponds to any of the polynucleotides of the invention can be obtained by screening appropriate cDNA or genomic DNA libraries under suitable hybridization conditions using any of the polynucleotides of the invention or a portion thereof as a probe. Alternatively, the polynucleotides of the invention may be used as the basis for suitable primer(s) that allow identification and/or amplification of genes in appropriate genomic DNA or cDNA libraries.

25

The nucleic acid sequences of the invention can be assembled from ESTs and sequences (including cDNA and genomic sequences) obtained from one or more public databases, such as dbEST, gbpri, and UniGene. The EST sequences can provide identifying sequence information, representative fragment or segment information, or novel segment information for the full-length gene.

30

The polynucleotides of the invention also provide polynucleotides including nucleotide sequences that are substantially equivalent to the polynucleotides recited above. Polynucleotides according to the invention can have, e.g., at least about 65%, at least about 70%, at least about 75%, at least about 80%, 81%, 82%, 83%, 84%, more typically at least about 85%, 86%, 87%, 88%, 89%, more typically at least about 90%, 91%, 92%, 93%, 94%, and even more typically at

least about 95%, 96%, 97%, 98%, 99% sequence identity to a polynucleotide recited above.

Included within the scope of the nucleic acid sequences of the invention are
5 nucleic acid sequence fragments that hybridize under stringent conditions to any
of the nucleotide sequences of the invention, or complements thereof, which
fragment is greater than about 5 nucleotides, preferably 7 nucleotides, more
preferably greater than 9 nucleotides and most preferably greater than 17
10 nucleotides. Fragments of, e.g. 15, 17, or 20 nucleotides or more that are
selective for (i. e. specifically hybridize to) any one of the polynucleotides of the
invention are contemplated. Probes capable of specifically hybridizing to a
polynucleotide can differentiate polynucleotide sequences of the invention from
other polynucleotide sequences in the same family of genes or can differentiate
human genes from genes of other species, and are preferably based on unique
15 nucleotide sequences.

The sequences falling within the scope of the present invention are not limited to
these specific sequences, but also include allelic and species variations thereof.
Allelic and species variations can be routinely determined by comparing the
20 sequence provided in the invention, a representative fragment thereof, or a
nucleotide sequence at least 90% identical, preferably 95% identical, to the
invention with a sequence from another isolate of the same species.
Furthermore, to accommodate codon variability, the invention includes nucleic
acid molecules coding for the same amino acid sequences as do the specific
25 ORFs disclosed herein. In other words, in the coding region of an ORF,
substitution of one codon for another codon that encodes the same amino acid is
expressly contemplated.

The term "stringent" is used to refer to conditions that are commonly understood
30 in the art as stringent. Stringent conditions can include highly stringent conditions
(i.e., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% sodium dodecyl
sulfate (SDS), 1 mM EDTA at 65°C., and washing in 0.1.times. SSC/0.1% SDS
at 68°C.), and moderately stringent conditions (i.e., washing in 0.2.times.
SSC/0.1% SDS at 42°C.). Other exemplary hybridization conditions are
35 described herein in the examples.

In instances of hybridization of deoxyoligonucleotides, additional exemplary stringent hybridization conditions include washing in 6.times. SSC/0.05% sodium pyrophosphate at 37°C (for 14-base oligonucleotides), 48°C (for 17-base oligos), 55°C (for 20-base oligonucleotides), and 60°C (for 23-base oligonucleotides).

5

SSC is defined as 0.15M NaCl, 0.015M Sodium Citrate, pH 7.2

By "identity" we mean the number or percentage (dependent on presentation of the results) of amino acid residues or nucleic acid residues in a candidate sequence that are identical with the amino acid residues or nucleic acid residues of the sequence of interest, after aligning the sequences and introducing gaps, if necessary to achieve maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity.

15 The percentage sequence identity between two polynucleotides or polypeptides may be determined using suitable computer programs, for example the GAP program of the University of Wisconsin Genetic Computing Group and it will be appreciated that percent identity is calculated in relation to polypeptides whose sequence has been aligned optimally. The alignment may alternatively be carried
20 out using the Clustal W program (Thompson *et al.*, (1994) *Nucleic Acids Res.* **22**, 4673-80). The parameters used may be as follows: fast pairwise alignment parameters: K-tuple(word) size; 1, window size; 5, gap penalty; 3, number of top diagonals; 5. Scoring method: x percent; multiple alignment parameters: gap open penalty; 10, gap extension penalty; 0.05. Scoring matrix: BLOSUM.

25

As used herein, "substantially equivalent" or "substantially similar" can refer both to nucleotide and amino acid sequences, for example a mutant sequence, that varies from a reference sequence by one or more substitutions, deletions, or additions, the net effect of which does not result in an adverse functional
30 dissimilarity between the reference and subject sequences. Typically, such a substantially equivalent sequence varies from one of those listed herein by no more than about 35% (i.e., the number of individual residue substitutions, additions, and/or deletions in a substantially equivalent sequence, as compared to the corresponding reference sequence, divided by the total number of residues
35 in the substantially equivalent sequence is about 0.35 or less). Such a sequence is said to have 65% sequence identity to the listed sequence. In one

embodiment, a substantially equivalent, e.g., mutant, sequence of the invention varies from a listed sequence by no more than 30% (70% sequence identity); in a variation of this embodiment, by no more than 25% (75% sequence identity); and in a further variation of this embodiment, by no more than 20% (80% sequence

5 identity) and in a further variation of this embodiment, by no more than 10% (90% sequence identity) and in a further variation of this embodiment, by no more than 5% (95% sequence identity). Substantially equivalent, e.g., mutant, amino acid sequences according to the invention preferably have at least 80% sequence identity with a listed amino acid sequence, more preferably at least 85%

10 sequence identity, more preferably at least 90% sequence identity, more preferably at least 95% sequence identity, more preferably at least 98% sequence identity, and most preferably at least 99% sequence identity.

Substantially equivalent nucleotide sequence of the invention can have lower percent sequence identities, taking into account, for example, the redundancy or 15 degeneracy of the genetic code. Preferably, the nucleotide sequence has at least about 65% identity, more preferably at least about 75% identity, more preferably at least about 80% sequence identity, more preferably at least 85% sequence identity, more preferably at least 90% sequence identity, more preferably at least about 95% sequence identity, more preferably at least 98% sequence identity,

20 and most preferably at least 99% sequence identity. For the purposes of the present invention, sequences having substantially equivalent biological activity and substantially equivalent expression characteristics are considered substantially equivalent. For the purposes of determining equivalence, truncation of the mature sequence (e.g., via a mutation which creates a spurious stop 25 codon) should be disregarded. Sequence identity may be determined, e.g., using the Jotun Hein method (Hein, J. (1990) *Methods Enzymol.* 183:626-645). Identity between sequences can also be determined by other methods known in the art, e.g. by varying hybridization conditions.

30 The invention further provides a peptide molecule according to the invention for use in medicine and/or a nucleic acid molecule according to the invention for use in medicine.

35 Preferably, the invention provides a peptide molecule according to the invention and/or a nucleic acid molecule according to the invention for use in preventing and/or treating a non-cancerous condition or a cancerous condition.

The invention further provides the use of a peptide molecule or a nucleic acid molecule of the invention in the manufacture of a medicament for preventing and/or treating a non-cancerous condition or a cancerous condition.

5

In a further aspect, the invention provides a pharmaceutical composition comprising or consisting of a peptide molecule according to the invention and a pharmaceutically-acceptable excipient.

10 In a further aspect, the invention provides a pharmaceutical composition comprising or consisting of a nucleic acid molecule according to the invention and a pharmaceutically-acceptable excipient.

15 The molecules, medicaments and pharmaceutical compositions of the present invention may be delivered using an injectable sustained-release drug delivery system. These are designed specifically to reduce the frequency of injections. An example of such a system is Nutropin Depot which encapsulates recombinant human growth hormone (rhGH) in biodegradable microspheres that, once injected, release rhGH slowly over a sustained period. Preferably, delivery is
20 performed intra-muscularly (i.m.) and/or sub-cutaneously (s.c.) and/or intravenously (i.v.).

25 The molecules, medicaments and pharmaceutical compositions of the present invention can be administered by a surgically implanted device that releases the drug directly to the required site. For example, Vitraser releases ganciclovir directly into the eye to treat CMV retinitis. The direct application of this toxic agent to the site of disease achieves effective therapy without the drug's significant systemic side-effects.

30 Electroporation therapy (EPT) systems can also be employed for the administration of the agents, medicaments and pharmaceutical compositions of the invention. A device which delivers a pulsed electric field to cells increases the permeability of the cell membranes to the drug, resulting in a significant enhancement of intracellular drug delivery.

35

The molecules, medicaments and pharmaceutical compositions of the invention can also be delivered by electroincorporation (EI). EI occurs when small particles of up to 30 microns in diameter on the surface of the skin experience electrical pulses identical or similar to those used in electroporation. In EI, these particles 5 are driven through the stratum corneum and into deeper layers of the skin. The particles can be loaded or coated with drugs or genes or can simply act as "bullets" that generate pores in the skin through which the drugs can enter.

An alternative method of delivery of the molecules, medicaments and 10 pharmaceutical compositions of the invention is the ReGel injectable system that is thermo-sensitive. Below body temperature, ReGel is an injectable liquid while at body temperature it immediately forms a gel reservoir that slowly erodes and dissolves into known, safe, biodegradable polymers. The active substance is delivered over time as the biopolymers dissolve.

15 The molecules, medicaments and pharmaceutical compositions of the invention can also be delivered orally. The process employs a natural process for oral uptake of vitamin B₁₂ and/or vitamin D in the body to co-deliver proteins and peptides. By riding the vitamin B₁₂ and/or vitamin D uptake system, the nucleic acids, molecules and pharmaceutical formulations of the invention can move 20 through the intestinal wall. Complexes are synthesised between vitamin B₁₂ analogues and/or vitamin D analogues and the drug that retain both significant affinity for intrinsic factor (IF) in the vitamin B₁₂ portion/vitamin D portion of the complex and significant bioactivity of the active substance of the complex.

25 The molecules, medicaments and pharmaceutical compositions of the invention can be introduced to cells by "Trojan peptides". These are a class of polypeptides called penetratins which have translocating properties and are capable of carrying hydrophilic compounds across the plasma membrane. This 30 system allows direct targeting of oligopeptides to the cytoplasm and nucleus, and may be non-cell type specific and highly efficient. See Derossi *et al.* (1998), Trends Cell Biol 8, 84-87.

35 Preferably, the medicament and/or pharmaceutical composition of the present invention is a unit dosage containing a daily dose or unit, daily sub-dose or an appropriate fraction thereof, of the active ingredient.

The molecules, medicaments and pharmaceutical compositions of the invention will normally be administered orally or by any parenteral route, in the form of a pharmaceutical composition comprising the active ingredient, optionally in the 5 form of a non-toxic organic, or inorganic, acid, or base, addition salt, in a pharmaceutically acceptable dosage form. Depending upon the disorder and patient to be treated, as well as the route of administration, the compositions may be administered at varying doses.

10 In human therapy, the molecules, medicaments and pharmaceutical compositions of the invention can be administered alone but will generally be administered in admixture with a suitable pharmaceutical excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.

15 For example, the molecules, medicaments and pharmaceutical compositions of the invention can be administered orally, buccally or sublingually in the form of tablets, capsules, ovules, elixirs, solutions or suspensions, which may contain flavouring or colouring agents, for immediate-, delayed- or controlled-release 20 applications. The molecules, medicaments and pharmaceutical compositions of the invention may also be administered via intracavernosal injection.

Such tablets may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine, 25 disintegrants such as starch (preferably corn, potato or tapioca starch), sodium starch glycollate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxy-propylcellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl 30 behenate and talc may be included.

Solid compositions of a similar type may also be employed as fillers in gelatin capsules. Preferred excipients in this regard include lactose, starch, cellulose, milk sugar or high molecular weight polyethylene glycols. For aqueous 35 suspensions and/or elixirs, the agents of the invention may be combined with various sweetening or flavouring agents, colouring matter or dyes, with

emulsifying and/or suspending agents and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof.

- The molecules, medicaments and pharmaceutical compositions of the invention
5 can also be administered parenterally, for example, intravenously, intra-arterially, intraperitoneally, intra-theccally, intraventricularly, intrasternally, intracranially, intra-muscularly or subcutaneously, or they may be administered by infusion techniques. They are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the
10 solution isotonic with blood. The aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.
- 15 Medicaments and pharmaceutical compositions suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening
20 agents. The medicaments and compositions may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules
25 and tablets of the kind previously described.

For oral and parenteral administration to human patients, the daily dosage level of the molecules, medicaments and pharmaceutical compositions of the invention will usually be from 0.1 to 100 mg per adult per day administered in single or
30 divided doses.

Thus, for example, the tablets or capsules of the molecules of the invention may contain from 0.1mg to 100mg of active agent for administration singly or two or more at a time, as appropriate. The physician in any event will determine the
35 actual dosage which will be most suitable for any individual patient and it will vary with the age, weight and response of the particular patient. The above dosages

are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited and such are within the scope of this invention.

5 The molecules, medicaments and pharmaceutical compositions of the invention can also be administered intranasally or by inhalation and are conveniently delivered in the form of a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray or nebuliser with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane,
10 dichlorotetrafluoro-ethane, a hydrofluoroalkane such as 1,1,1,2-tetrafluoroethane (HFA 134A, or 1,1,1,2,3,3-heptafluoropropane (HFA 227EA.), carbon dioxide or other suitable gas. In the case of a pressurised aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurised container, pump, spray or nebuliser may contain a solution or suspension of the
15 active agent, e.g. using a mixture of ethanol and the propellant as the solvent, which may additionally contain a lubricant, e.g. sorbitan trioleate. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated to contain a powder mix of a agent of the invention and a suitable powder base such as lactose or starch.

20 Aerosol or dry powder formulations are preferably arranged so that each metered dose or "puff" contains at least 0.1 mg of a molecule of the invention for delivery to the patient. It will be appreciated that the overall daily dose with an aerosol will vary from patient to patient, and may be administered in a single dose or, more
25 usually, in divided doses throughout the day.

30 Alternatively, the molecules, medicaments and pharmaceutical compositions of the invention can be administered in the form of a suppository or pessary, or they may be applied topically in the form of a lotion, solution, cream, gel, ointment or dusting powder. The molecules, medicaments and pharmaceutical compositions of the invention may also be transdermally administered, for example, by the use of a skin patch. They may also be administered by the ocular route, particularly for treating diseases of the eye.

35 For ophthalmic use, the molecules, medicaments and pharmaceutical compositions of the invention can be formulated as micronised suspensions in

isotonic, pH adjusted, sterile saline, or, preferably, as solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzylalkonium chloride. Alternatively, they may be formulated in an ointment such as petrolatum.

5

For application topically to the skin, the molecules, medicaments and pharmaceutical compositions of the invention can be formulated as a suitable ointment containing the active agent suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white 10 petrolatum, propylene glycol, polyoxyethylene polyoxypropylene agent, emulsifying wax and water. Alternatively, they can be formulated as a suitable lotion or cream, suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, 15 benzyl alcohol and water.

Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavoured basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as 20 gelatin and glycerin, or sucrose and acacia; and mouth-washes comprising the active ingredient in a suitable liquid carrier.

Generally, in humans, oral or parenteral administration of the molecules, medicaments and pharmaceutical compositions of the invention agents of the 25 invention is the preferred route, being the most convenient.

For veterinary use, the molecules, medicaments and pharmaceutical compositions of the invention is administered as a suitably acceptable formulation in accordance with normal veterinary practice and the veterinary surgeon will 30 determine the dosing regimen and route of administration which will be most appropriate for a particular animal.

Conveniently, the formulation is a pharmaceutical formulation. Advantageously, the formulation is a veterinary formulation.

35

Preferably, the pharmaceutical composition is for use in preventing or treating a non-cancerous condition.

In a further aspect, the invention provides a method of preventing and/or treating

5 a non-cancerous condition or a cancerous condition in a patient comprising the step of administering to a patient in need thereof an effective amount of a peptide molecule according to the invention or a nucleic acid molecule according to the invention, or a pharmaceutical composition according to the invention.

10 By "therapeutically effective amount" or "effective amount" we mean an amount of a peptide molecule according to the invention or a nucleic acid molecule according to the invention, that when administered to the subject either alone or in combination with another agent, ameliorates a symptom of the disease, disorder, or condition.

15 By "autoimmune disease" we include the meaning of cases where it can be shown that the autoimmune process contributes to the pathogenesis of a disease. Such diseases are typically associated with a T helper lymphocyte-1 (Th-1) type immune response.

20 By "allergic conditions" we include the meaning of conditions associated with a T helper lymphocyte-2 (Th-2) type immune response. In allergic reaction, high IgE levels occur and Th-2 immune responses predominate over Th-1 responses, resulting in inflammatory response. Examples of allergic conditions include the
25 following: asthma, rhinitis/hay fever, eczema and anaphylaxis.

By "adjuvant" we mean any substance which, when incorporated into or administered simultaneously with antigen, potentiates the immune response.

30 Typically, the non-cancerous condition is selected from the group comprising or consisting of: autoimmune disorders, such as haemolytic anaemia, thrombocytopenia, thyroiditis, pernicious anaemia, Addison's disease, autoimmune diabetes, myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus, atherosclerosis, and autoimmune encephalitis; allergic conditions
35 such as eczema, dermatitis, allergic rhinitis, allergic conjunctivitis; allergic airways diseases; hyper-eosinophilic syndrome; contact dermatitis, food allergy; and

respiratory diseases characterized by eosinophilic airway inflammation and airway hyper-responsiveness, such as allergic asthma, intrinsic asthma, allergic bronchopulmonary aspergillosis, eosinophilic pneumonia, allergic bronchitis bronchiectasis, occupational asthma, reactive airway disease syndrome, 5 interstitial lung disease, hyper-eosinophilic syndrome, parasitic lung disease.

Further examples of autoimmune conditions are, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, 10 autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein (or antagonists thereof, including antibodies) of the present invention may also be useful in the treatment of allergic reactions and conditions (e.g., anaphylaxis, serum sickness, drug reactions, food allergies, insect venom allergies, 15 mastocytosis, allergic rhinitis, hypersensitivity pneumonitis, urticaria, angioedema, eczema, atopic dermatitis, allergic contact dermatitis, erythema multiforme, Stevens-Johnson syndrome, allergic conjunctivitis, atopic keratoconjunctivitis, venereal keratoconjunctivitis, giant papillary conjunctivitis and contact allergies), such as asthma (particularly allergic asthma) or other respiratory problems.

20 Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein (or antagonists thereof) of the present invention. The therapeutic effects of the polypeptides or antagonists thereof on allergic reactions can be evaluated by *in vivo* animals models such as the cumulative contact enhancement test (Lastbom *et al.*, 25 Toxicology 125: 59-66, 1998), skin prick test (Hoffmann *et al.*, Allergy 54: 446-54, 1999), guinea pig skin sensitization test (Vohr *et al.*, Arch. Toxocol. 73: 501-9), and murine local lymph node assay (Kimber *et al.*, J. Toxicol. Environ. Health 53: 563-79).

30 Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan *et al.*, Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, *In vitro* assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Herrmann *et al.*, Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann *et al.*, J. Immunol. 128:1968-35 1974, 1982; Handa *et al.*, J. Immunol. 135:1564-1572, 1985; Takai *et al.*, I.

Immunol. 137:3494-3500, 1986; Takai *et al.*, *J. Immunol.* 140:508-512, 1988; Bowman *et al.*, *J. Virology* 61:1992-1998; Bertagnolli *et al.*, *Cellular Immunology* 133:327-341, 1991; Brown *et al.*, *J. Immunol.* 153:3079-3092, 1994.

- 5 Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, *J. Immunol.* 144:3028-3033, 1990; and Assays for B cell function: *In vitro* antibody production, Mond, J. J. and Brunswick, M. In
10 Current Protocols in Immunology. J. E. Coligan *et al.*, eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without
15 limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan *et al.*, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, *In vitro* assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai *et al.*, *J. Immunol.* 137:3494-3500, 1986; Takai *et al.*, *J. Immunol.* 140:508-512, 1988; Bertagnolli *et al.*, *J. Immunol.*
20 149:3778-3783, 1992.

Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery *et al.*, *J. Immunol.* 134:536-544, 1995; Inaba *et al.*, *J. Experimental Medicine* 173:549-559, 1991; Macatonia *et al.*, *J. Immunol.* 154:5071-5079, 1995; Porgador *et al.*, *J. Experimental Medicine* 182:255-260, 1995; Nair *et al.*, *J. Virology* 67:4062-4069, 1993; Huang *et al.*, *Science* 264:961-965, 1994; Macatonia *et al.*, *J. Experimental Medicine* 169:1255-1264, 1989; Bhardwaj *et al.*, *J. Clinical Investigation* 94:797-807, 1994; and Inaba *et al.*, *J. Experimental Medicine* 172:631-640, 1990.

Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in:
35 Darzynkiewicz *et al.*, *Cytometry* 13:795-808, 1992; Gorczyca *et al.*, *Leukemia* 7:659-670, 1993; Gorczyca *et al.*, *Cancer Research* 53:1945-1951, 1993; Itoh et

al., *Cell* 66:233-243, 1991; Zacharchuk, *J. Immunol.* 145:4037-4045, 1990; Zamai et al., *Cytometry* 14:891-897, 1993; Gorczyca et al., *Int. J. Oncol.* 1:639-648, 1992.

- 5 Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., *Blood* 84:111-117, 1994; Fine et al., *Cellular Immunology* 155:111-122, 1994; Galy et al., *Blood* 85:2770-2778, 1995; Toki et al., *Proc. Natl. Acad. Sci. USA* 88:7548-7551, 1991.

10

- Compositions of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Compositions with such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation intimation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Compositions of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material. Compositions of this invention may be utilized to prevent or treat conditions such as, but not limited to, sepsis, acute pancreatitis, endotoxin shock, cytokine induced shock, rheumatoid arthritis, chronic inflammatory arthritis, pancreatic cell damage from diabetes mellitus type 1, graft versus host disease, inflammatory bowel disease, inflammation associated with pulmonary disease, other autoimmune disease or inflammatory disease, an antiproliferative agent such as for acute or chronic myelogenous leukemia or in the prevention of premature labor secondary to intrauterine infections.
- 35 In a preferred embodiment, the non-cancerous condition is asthma; alternatively, the non-cancerous condition is arthritis.

The immunosuppressive effects of the compositions of the invention against rheumatoid arthritis is determined in an experimental animal model system. The experimental model system is adjuvant induced arthritis in rats, and the protocol 5 is described by J. Holoshitz, et al., 1983, *Science*, 219:56, or by B. Waksman et al., 1963, *Int. Arch. Allergy Appl. Immunol.*, 23:129. Induction of the disease can be caused by a single injection, generally intradermally, of a suspension of killed *Mycobacterium tuberculosis* in complete Freund's adjuvant (CFA). The route of injection can vary, but rats may be injected at the base of the tail with an 10 adjuvant mixture. The polypeptide is administered in phosphate buffered solution (PBS) at a dose of about 1-5 mg/kg. The control consists of administering PBS only.

The procedure for testing the effects of the test compound would consist of 15 intradermally injecting killed *Mycobacterium tuberculosis* in CFA followed by immediately administering the test compound and subsequent treatment every other day until day 24. At 14, 15, 18, 20, 22, and 24 days after injection of *Mycobacterium CFA*, an overall arthritis score may be obtained as described by J. Holoskitz above. An analysis of the data would reveal that the test compound 20 would have a dramatic affect on the swelling of the joints as measured by a decrease of the arthritis score.

Cancer treatments promote tumor regression by inhibiting tumor cell proliferation, 25 inhibiting angiogenesis (growth of new blood vessels that is necessary to support tumor growth) and/or prohibiting metastasis by reducing tumor cell motility or invasiveness. Therapeutic compositions of the invention may be effective in adult and pediatric oncology including in solid phase tumors/malignancies, locally advanced tumors, human soft tissue sarcomas, metastatic cancer, including lymphatic metastases, blood cell malignancies including multiple myeloma, acute 30 and chronic leukemias, and lymphomas, head and neck cancers including mouth cancer, larynx cancer and thyroid cancer, lung cancers including small cell carcinoma and non-small cell cancers, breast cancers including small cell carcinoma and ductal carcinoma, gastrointestinal cancers including esophageal cancer, stomach cancer, colon cancer, colorectal cancer and polyps associated 35 with colorectal neoplasia, pancreatic cancers, liver cancer, urologic cancers including bladder cancer and prostate cancer, malignancies of the female genital

tract including ovarian carcinoma, uterine (including endometrial) cancers, and solid tumor in the ovarian follicle, kidney cancers including renal cell carcinoma, brain cancers including intrinsic brain tumors, neuroblastoma, astrocytic brain tumors, gliomas, metastatic tumor cell invasion in the central nervous system,
5 bone cancers including osteomas, skin cancers including malignant melanoma, tumor progression of human skin keratinocytes, squamous cell carcinoma, basal cell carcinoma, hemangiopericytoma and Kaposi's sarcoma.

Polypeptides, polynucleotides, or modulators of polypeptides of the invention
10 (including inhibitors and stimulators of the biological activity of the polypeptide of the invention) may be administered to treat cancer. Therapeutic compositions can be administered in therapeutically effective dosages alone or in combination with adjuvant cancer therapy such as surgery, chemotherapy, radiotherapy, thermotherapy, and laser therapy, and may provide a beneficial effect, e.g.
15 reducing tumor size, slowing rate of tumor growth, inhibiting metastasis, or otherwise improving overall clinical condition, without necessarily eradicating the cancer.

The composition can also be administered in therapeutically effective amounts as
20 a portion of an anti-cancer cocktail. An anti-cancer cocktail is a mixture of the polypeptide or modulator of the invention with one or more anti-cancer drugs in addition to a pharmaceutically acceptable carrier for delivery. The use of anti-cancer cocktails as a cancer treatment is routine. Anti-cancer drugs that are well known in the art and can be used as a treatment in combination with the
25 polypeptide or modulator of the invention include: Actinomycin D, Aminoglutethimide, Asparaginase, Bleomycin, Busulfan, Carboplatin, Carmustine, Chlorambucil, Cisplatin (cis-DDP), Cyclophosphamide, Cytarabine HCl (Cytosine arabinoside), Dacarbazine, Dactinomycin, Daunorubicin HCl, Doxorubicin HCl, Estramustine phosphate sodium, Etoposide (V16-213), Floxuridine, 5-Fluorouracil
30 (5-Fu), Flutamide, Hydroxyurea (hydroxycarbamide), Ifosfamide, Interferon Alpha-2a, Interferon Alpha-2b, Leuprolide acetate (LHRH-releasing factor analog), Lomustine, Mechlorethamine HCl (nitrogen mustard), Melphalan, Mercaptopurine, Mesna, Methotrexate (MTX), Mitomycin, Mitoxantrone HCl, Octreotide, Plicamycin, Procarbazine HCl, Streptozocin, Tamoxifen citrate, Thioguanine,
35 Thiotepa, Vinblastine sulfate, Vincristine sulfate, Amsacrine, Azacitidine,

Hexamethylmelamine, Interleukin-2, Mitoguazone, Pentostatin, Semustine, Teniposide, and Vindesine sulfate.

In addition, therapeutic compositions of the invention may be used for prophylactic treatment of cancer. There are hereditary conditions and/or environmental situations (e.g. exposure to carcinogens) known in the art that predispose an individual to developing cancers. Under these circumstances, it may be beneficial to treat these individuals with therapeutically effective doses of the polypeptide of the invention to reduce the risk of developing cancers.

10

In vitro models can be used to determine the effective doses of the polypeptide of the invention as a potential cancer treatment. These *in vitro* models include proliferation assays of cultured tumor cells, growth of cultured tumor cells in soft agar (see Freshney, (1987) *Culture of Animal Cells: A Manual of Basic Technique*, Wiley-Liss, New York, NY Ch 18 and Ch 21), tumor systems in nude mice as described in Giovanella *et al.*, *J. Natl. Can. Inst.*, 52: 921-30 (1974), mobility and invasive potential of tumor cells in Boyden Chamber assays as described in Pilkington *et al.*, *Anticancer Res.*, 17: 4107-9 (1997), and angiogenesis assays such as induction of vascularization of the chick chorioallantoic membrane or induction of vascular endothelial cell migration as described in Ribatta *et al.*, *Intl. J. Dev. Biol.*, 40: 1189-97 (1999) and Li *et al.*, *Clin. Exp. Metastasis*, 17:423-9 (1999), respectively. Suitable tumor cells lines are available, e.g. from American Type Tissue Culture Collection catalogs.

25

Leukemias and related disorders may be treated or prevented by administration of a therapeutic that promotes or inhibits function of the polynucleotides and/or polypeptides of the invention. Such leukemias and related disorders include but are not limited to acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia, chronic leukemia, chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia (for a review of such disorders, see Fishman *et al.*, 1985, *Medicine*, 2d Ed., J. B. Lippincott Co., Philadelphia).

30

In a further aspect, the invention provides a peptide molecule according to the invention or a nucleic acid molecule according to the invention for use in the relief of pain.

In a further aspect, the invention provides a pharmaceutical composition which is for use in the relief of pain. Preferred pharmaceutical compositions according to the invention are described above and in the accompanying examples.

5

In a further aspect, the invention provides the use of a peptide molecule according to the invention or a nucleic acid molecule according to the invention in the manufacture of a medicament for the relief of pain.

- 10 By "use in the relief of pain" we include any treatment which influences the pain felt by an individual, such influence including a delay in the onset, a reduction in the severity, a reduction of the duration, and/or the removal of the feeling of pain. (and/or analgesia and/or hyperanalgesia) in a human or animal patient. By "pain" we also include analgesia and/or hyperanalgesia - by "hyperalgesia" we mean an
15 earlier onset, an increase in the severity, an increase of the duration, and/or increased susceptibility to the feeling of pain.

In a preferred embodiment, the medicament further comprises at least one additive for assisting or augmenting the action of the peptide molecule or nucleic
20 acid molecule. Typically, the additive is selected from at least one of paracetamol, aspirin, ibuprofen, other non-steroidal anti-inflammatory drugs (NSAIDS), cyclooxygenase-2-selective inhibitors (CSIs), opiates.

By "additive" we include an ingredient that is provided in addition to the main
25 medicament and that is pharmacologically active either independently or in combination with the main medicament, whereby its presence in the medicament assists or augments the action of the main medicament.

Preferably, the medicament provides prolonged or sustained pain relief.

30

Advantageously, in the use according to the invention, the daily dosage level will be from 0.0001 to 100,000 mg, administered in single or divided doses; preferably, the daily dosage level is 0.0001 to 1000 mg.

35 Preferred pharmaceutical formulations include those in which the active ingredient is present in at least 1% (such as at least 10%, preferably in at least

30% and most preferably in at least 50%) by weight. That is, the ratio of active ingredient to the other components (i.e. the addition of adjuvant, diluent and carrier) of the pharmaceutical composition is at least 1:99 (e.g. at least 10:90, preferably at least 30:70 and most preferably at least 50:50) by weight.

5

Typically, the time between dose administration to the patient is between six and twelve hours; in a preferred embodiment, the time between dose administration to the patient is between nine and twelve hours after the previous dose; more preferably, the time between dose administration to the patient is between twelve

10 hours and twelve days; even more preferably, the time between dose administration to the patient is between twelve days and six months.

In a preferred embodiment, the invention provides a use wherein the medicament of the invention is used to relieve pain in a human or animal patient.

15

Preferably, the pharmaceutical composition or the medicament of the invention is formulated to permit administration by at least one route selected from the group comprising or consisting of: intranasal; oral; parenteral; topical; ophthalmic; suppository; pessary; or inhalation routes. Formulations suitable for such 20 administration routes are well known to those in the art of pharmacy and medicine and exemplary formulations are described above and in the accompanying examples.

Preferably, the pain is selected from the group comprising or consisting of: backache; headache; toothache; earache; arthritis; gout; soft tissue trauma; ligament and/or tendon traumatic damage; broken bones; cancer; post-operative 25 pain; menstrual pain; obstetric pain; renal tract pain; visceral pain; burns; abscesses; and other infections.

30 In a further aspect, the invention provides a method of relieving pain in a patient comprising the step of administering to a patient in need thereof an effective amount of a peptide molecule of the invention and/or a nucleic acid molecule of the invention and/or pharmaceutical composition of the invention.

In a further aspect, the invention provides the use of a peptide molecule according to the invention and/or a nucleic acid molecule according to the invention as an adjuvant.

- 5 In a further aspect, the invention provides an adjuvant system comprising (i) a peptide molecule according to the invention and/or a nucleic acid molecule according to the invention and (ii) an antigen.

Preferably, the antigen is selected from the group comprising or consisting of:

- 10 anthrax antigen; cholera antigen; diphtheria antigen; haemophilus influenza b (Hib) antigen; hepatitis A antigen; hepatitis B antigen; influenza antigen; Japanese encephalitis antigen; measles, mumps and rubella (MMR) antigen; meningococcal antigen; pertussis antigen; pneumococcal antigen; poliomyelitis antigen; rabies antigen; rubella antigen; smallpox and/or vaccinia antigen; tetanus 15 antigen; tick-borne encephalitis antigen; tuberculosis antigen; typhoid antigen; varicella/herpes zoster antigen; yellow fever antigen; and veterinary vaccine antigen.

- 20 In a further aspect, the invention provides a method of stimulating cytokine production in a cell comprising the step of administering a peptide molecule according to the invention or a nucleic acid molecule according to the invention.

Preferably, cytokine production is increased at least 10-fold relative to normal levels.

- 25 Normal levels for a particular cell type can be readily determined using a control sample that is not exposed to the polypeptide or polynucleotide of the invention in any of the assays discussed below or as described in the examples.

- 30 A polypeptide of the present invention may exhibit activity relating to cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. A polynucleotide of the invention can encode a polypeptide exhibiting such attributes. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor-dependent cell 35 proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of therapeutic compositions of the present invention

is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+(preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e, CMK, HUVEC, and Caco.

5

Assays for T-cell or thymocyte proliferation include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan *et al.*, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, *In vitro* assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in

10 Humans); Takai *et al.*, *J. Immunol.* 137:3494-3500, 1986; Bertagnolli *et al.*, *J. Immunol.* 145:1706-1712, 1990; Bertagnolli *et al.*, *Cellular Immunology* 133:327-341, 1991; Bertagnolli, *et al.*, *I. Immunol.* 149:3778-3783, 1992; Bowman *et al.*, *I. Immunol.* 152:1756-1761, 1994.

15 Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A. M. and Shevach, E. M. In Current Protocols in Immunology. J. E. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human interleukin- γ , Schreiber, 20 R. D. In Current Protocols in Immunology. J. E. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.

Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and 25 Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L. S. and Lipsky, P. E. In Current Protocols in Immunology. J. E. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries *et al.*, *J. Exp. Med.* 173:1205-1211, 1991; Moreau *et al.*, *Nature* 336:690-692, 1988; Greenberger *et al.*, *Proc. Natl. Acad. Sci. USA* 80:2931-2938, 1983; Measurement of mouse and human 30 interleukin 6--Nordan, R. In Current Protocols in Immunology. J. E. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 83:1857-1861, 1986; Measurement of human Interleukin 11--Bennett, F., Giannotti, J., Clark, S. C. and Turner, K. J. In Current Protocols in Immunology. J. E. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 35 1991; Measurement of mouse and human Interleukin 9--Ciarletta, A., Giannotti,

J., Clark, S. C. and Turner, K. J. In Current Protocols in Immunology. J. E. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

Assays for T-cell clone responses to antigens (which will identify, among others,

5 proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, *In vitro* assays for Mouse
10 Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger *et al.*, *Proc. Natl. Acad. Sci. USA* 77:6091-6095, 1980; Weinberger *et al.*, *Eur. J. Immun.* 11:405-411, 1981; Takai *et al.*, *J. Immunol.* 137:3494-3500, 1986; Takai *et al.*, *J. Immunol.* 140:508-512, 1988.

15

In a preferred embodiment, the cytokine is selected from the group comprising or consisting of: IL-1 β ; IL-2; IL-6; IL-8; IL-10; IL-12; TNF- α ; Interferon- γ ; GM-CSF.

The invention further provides a method of assessing the presence and/or

20 amount in a sample of a peptide molecule according to the invention or a nucleic acid molecule according to the invention comprising or consisting of the steps of:

- i) providing a test sample;
- ii) contacting the test sample with a cell;
- 25 iii) measuring and/or detecting the level of production of one or more cytokine by the cell;
- iv) comparing the level of production of one or more cytokine in (iii) with the level of production of the one or more cytokine in a control sample

30

wherein a higher level of production of one or more cytokine induced by the test sample compared to the control sample indicates the presence and/or amount in the test sample of a peptide molecule according to the invention or a nucleic acid molecule according to the invention.

35

"MT60.1", "Mtcpn60.1", "cpn 60.1", "60.1" and "chaperonin 60.1" are used interchangeably throughout the specification to refer to the amino acid sequence shown in Figure 25.

The listing or discussion of an apparently prior-published document in this specification should not necessarily be taken as an acknowledgement that the document is part of the states of the art or is common general knowledge.

- 5 Preferred, non-limiting examples which embody certain aspects of the invention will now be described, with reference to the following figures:

Figure 1. The recruitment of eosinophils to the airways 24 h after repeated ovalbumin challenged was inhibited in mice treated with Cpn60.1, Cpn10 but not Cpn60.2. Vertical lines represent standard error of mean (SEM) of 4–12 (Cpn60.1), 3–5 (Cpn60.2), 4–10 (Cpn10) animals per group. *Significant reduction in percentage of eosinophils compared with ovalbumin alone.

Figure 2. The Bronchial hyper-responsiveness to methacholine 24 h after repeated ovalbumin challenged was reduced in mice treated with Cpn60.1, Cpn10 but not Cpn60.2 (n=16-17). Vertical lines represent SEM.

Figure 3. The levels of cytokines in BAL fluid 24 h after repeated ovalbumin challenge was inhibited in mice treated with Cpn60.1. Vertical lines represent SEM. * Significant reduction in levels of cytokines compared with ovalbumin alone (n=8-10).

Figure 4. Transfer of Cpn10 pre-treated dendritic cells (10 μ g/ml) *in vitro* to OVA-sensitized recipient mice significantly inhibited eosinophils migration to the lung. Vertical lines represent SEM. * Significant reduction in number of eosinophils compared with sensitized mice instilled with untreated DC's (n=9-15).

Figure 5. Dendritic cells pulsed with Cpn60.1 for 48 hours produced IL12 in a dose-dependant manner. Pre-treatment of dendritic cells with Cpn10 (10 μ g/ml) induced low levels of IL12. Cells were stimulated with the chaperonins for 48h and tested in quadruplicate and each column represents the mean of two experiments. Vertical lines represent Standard Deviation (SD).

Figure 6. Pre-incubation of dendritic cells with Cpn60.1 for 24 hours inhibit IL12 production induced by LPS. Cells were stimulated with the chaperonins for 248h and with LPS for further 24h. All concentrations were tested in quadruplicate and

each column represents the mean of two experiments. Vertical lines represent SD.

Figure 7. Pre-treatment of dendritic cells with Cpn60.1 or Cpn10 (10 μ g/ml)

5 suppressed the levels of IL4 in a co-culture of dendritic cells and RD11.10 T cells. IL5 and IL10 were not detected in this culture. Dendritic cells were stimulated with the chaperonins for 24h before co-culturing them with DO.11 cells. The co-culture was maintained for 6 days and cells were stimulated with anti-CD3 and anti-CD28 for further 24 hours. Supernatants were collected and tested in
10 quadruplicate. Vertical lines represent SD.

Figure 8. Pre-treatment of spleen cells of C57Bl/6 mice with various

concentrations of Cpn60.1 and its peptides induce IL-12 release *in vitro*. Medium
15 contained 5 μ g/ml of polymixin B. Cells were stimulated with the chaperonins for 24h and supernatants were tested in quadruplicate. Each line represents the mean of two experiments.

Figure 9. Spleen cells collected from TLR4 KO mice presented a reduced

response to the chaperonin 60.1 and its peptides when compared to their wild
20 type counterpart C57bl/6 mice. TLR2 KO mice also presented an inhibited response to the chaperonins. All concentrations were tested in quadruplicate. Vertical lines represent SD.

Figure 10. The recruitment of total cells to the airways 24 h after repeated

25 ovalbumin challenged was inhibited in mice treated with Cpn60 and Cpn60.1-peptide 4. Vertical lines represent SEM of 5-9 animals per group. * Significant reduction in number of total cells compared to sham group. **Significant reduction in number of total cells compared with ovalbumin alone.

Figure 11. The recruitment of eosinophils to the airways 24 h after repeated

ovalbumin challenged was inhibited in mice treated with Cpn60 and Cpn60.1-peptide 4. Vertical lines represent SEM of 5-9 animals per group. *Significant reduction in number of eosinophils compared to sham group. **Significant reduction in number of eosinophils compared with ovalbumin alone.

Figure 12. The levels of IL-5 in BAL fluid 24 h after repeated ovalbumin challenge was not significantly inhibited in mice treated with Cpn60.1 or Cpn60.1-peptide 4. Vertical lines represent SEM.

5 **Figure 13.** The levels of total IgE circulating in serum 24 h after repeated ovalbumin challenge was significantly inhibited in mice treated with Cpn60.1-peptide 4 (0.005 μ g/mouse). Vertical lines represent SEM. ** Significant increase in levels of total IgE compared to ovalbumin alone.

10 **Figure 14.** Effect of Cpn60.1 on mechanical hyperalgesia in CFA-treated rats (n=6).

Figure 15. Effect of Cpn60.1 on thermal hyperalgesia in CFA-treated rats (n=6).

15 **Figure 16.** Effect of Cpn60.1 on mechanical hyperalgesia in UV-treated rats (n=6).

Figure 17. Effect of Cpn60.1 on thermal hyperalgesia in UV-treated rats (n=6).

20 **Figure 18.** Pre-treatment of human peripheral blood monocytes with Cpn60.1 suppresses LPS-induced TNF-alpha secretion. Data shows an attenuation of TNF- α secretion with increasing concentration of Cpn60.1. Maximum inhibition at 1ng/ml although not significant. Data represented as mean \pm SEM (n=5).

25 **Figure 19.** Pre-treatment of human peripheral blood monocytes with Cpn60.1 suppresses LPS-induced TNF-alpha secretion in the presence of polymyxin-B. Data shows an attenuation of TNF- α secretion with increasing concentration of Cpn60.1. Maximum inhibition at 1ng/ml. Data represented as mean \pm SEM (n=5).

30 **Figure 20.** Pre-treatment of human peripheral blood monocytes with Cpn10 does not suppress LPS-induced TNF-alpha secretion. Cpn10 had no effect at inhibiting TNF- α secretion at any concentration when compared to LPS. Data represented as mean \pm SEM (n=5).

35

Figure 21. Pre-treatment of human peripheral blood monocytes with Cpn60.1 or Cpn60.1 peptides suppress TNF-alpha release induced by LPS. Data are expressed as the mean of two separate experiments in triplicate expressed as a percent of control values.

5

Figure 22. Total number of neutrophils recovered from lavage of increasing concentration of LPS (1 μ g/ml) vs. saline-challenged mice at 24 hours (n=4).

Figure 23. Total number of neutrophils recovered from lavage of LPS-treated 10 mice (1 μ g/ml) and Cpn60.1-treated mice at 24 hours (n=4).

Figure 24. Total number of neutrophils recovered from lavage of increasing concentration of LPS (1 μ g/ml) vs. saline-challenged mice at 24 hours (n=4). Cpn60.1-treated animals reduced LPS-induced neutrophilia. Significantly 15 inhibited in comparison to LPS-treated group (*p<0.05).

Figure 25. Peptides covering the equatorial domain of *Mycobacterium tuberculosis* Cpn60.1. The equatorial domain is marked by the solid black lines and boxes/arrows under the sequence.

20

Peptides 1,2,5,7,8,9,10 are highly surface-exposed and/or regions of high dissimilarity between Cpn60.1 and Cpn60.2 and should therefore be the potentially most interesting peptides. Peptides 3 and 9 are surface-exposed but towards the inner face of a putative oligomeric structure and are highly interesting 25 to study. Peptide 4 and 6 are both partly buried in the structure and may be of relatively lower potential interest.

Examples**Overview of Examples**

- 5 The objectives of our experiments were to investigate the anti-inflammatory properties of chaperonins in a model of allergic inflammation. The results extend our previous findings showing that both Cpn60.1 and Cpn10 inhibited allergic inflammatory responses *in vivo*, and at the cellular level were able to inhibit dendritic cell function which might explain the anti-inflammatory properties of
10 these molecules *in vivo*.

The structural determinant of this anti-inflammatory property of Cpn60.1 remains to be established. Therefore, various peptide sequences of Cpn60.1 were investigated for potential anti-inflammatory properties *in vitro* and *in vivo*. A
15 number of these peptides appeared to have immunomodulatory activity *in vitro* and anti-inflammatory properties *in vivo*, suggesting that the structural determinants of the activity residing within chaperonins is amenable to interrogation with the view of finding novel anti-inflammatory agents.

20

Example 1 - Effect of Cpn60.1 and 10 in a murine model of allergic inflammation:

Allergic diseases, including asthma are considered to be associated with over activity of Th2 lymphocytes, and so strategies designed to induce immune deviation may be useful in suppressing allergic inflammation in asthma. It has been shown that both *M. tuberculosis* and the vaccine *M. bovis* BCG, which is antigenically very similar to *M. tuberculosis* (Harboe M et al. *Scand J Immunol.* 1979; 9:115-24) can suppress allergic lung inflammation. Data from Helperby Therapeutics have confirmed that *M. tuberculosis* has three chaperonins, namely
25 60.1 , 60.2 , and 10. Moreover, we have previously demonstrated that Cpn10 and 60.1 but not 60.2 suppressed lung inflammation in a murine model of asthma
30 (Riffo-Vasquez, Y. et al., *Clin. Exp. Allergy*, 2004, 34:712-19).

Allergic inflammation in the lung is induced by 2 intraperitoneal injections of 10 μ g
35 of ovalbumin (OVA) in 1mg of alum with 7 days interval between them. Control animals receive alum only. On day 14, all animals are exposed to an aerosol of

OVA for 25 minutes, once a day for 3 consecutive days. All measurements are performed 24h after the last antigen challenge.

We have shown that intra-tracheal administration of 10 μ g of Cpn60.1 or Cpn10,

5 24h before the second injection of OVA and one hour before each antigen challenge can significantly inhibit airways inflammation (Figure 1), hyper-responsiveness (Figure 2) and cytokine release in the lung (Figure 3). However, the mechanism by these chaperonins exert this effect *in vivo* remain to be established.

10

Example 2 - Effect of Cpn10 and Cpn60.1 on murine dendritic cells function

It has been shown that mycobacterial heat shock proteins (hsp) can enhance

15 antigen processing and presentation by dendritic cells (DC) of exogenous proteins to T cells, without the need of complex formation between hsp and the protein (Chen K., et al., *J. Leuk. Biol.*, 2004, 75:1-7).

In order to clarify the mechanism by which Cpn10 and 60.1 regulated allergic lung

20 inflammation *in vivo*, we have investigated the effect of these chaperonins on bone marrow dendritic cell function *in vitro*.

Bone marrow cells from Balb/c mice were collected and cultured for 6 days in

complete Dulbecco's Modified Eagle Medium containing 8ng/ml of mouse GM-

25 CSF. On day 6 of culture, the cells were collected, re-plated for 1 hour for removal of adherent cells, washed and plated at 2x10⁶ cells/well in 6-wells plates for analysis of surface markers expression and transference experiments and at 10⁵ cells/well in 96-wells plate for cytokine measurements. In other experiments, cells were incubated at 10⁶ cells/well for 24h with the chaperonins and then 30 another further 24 h with LPS (10ng/ml).

The DC's were pre-treated *in vitro* for 24h with Cpn10 (10 μ g/ml) and then

administrated topically to the lungs of OVA-sensitized recipient mice. This

treatment significantly inhibited eosinophil migration to the lung (Figure 4),

35 reproducing the effect observed *in vivo* with the chaperonin itself.

Pre-treatment of DC *in vitro* with Cpn60.1 (0.1-30 µg/ml) induced the release of IL-12 in a dose dependent-manner. However, pre-treatment of DC with Cpn10 (10µg/ml) induced lower levels of IL-12 release in comparison to LPS and Cpn60.1 (Figure 5).

5

Pre-incubation of DC's with Cpn60.1 but not Cpn10 for 24 hours inhibited IL12 production induced by LPS (Figure 6).

DC pre-treated with Cpn60.1 (10µg/ml) or Cpn10 (10µg/ml) for 24h suppressed
10 the release of IL4 from RD11.10 T cells in a DC/T cell co-culture. After 6 days of culture, cells were stimulated with anti-CD3 and anti-CD28 for further 24 hours and supernatants collected. IL5 and IL10 were not detected in this culture (Figure 7).

Example 3 - The effect of Chaperonin 60.1 peptides *in vitro*

In order to determine the structural determinants of Chaperonin 60.1 responsible for the biological actions observed we have investigated the effect of 5 different peptide sequences designated in this study as peptide 1, 2, 3, 4 and 6 in various

5 peptide sequences designated in this study as peptide 1, 2, 3, 4 and 6 in various
in vitro biological assays.

The specific sequences are shown below:

Peptide name	Peptide sequence
Peptide 1 (p60.1_30)	LGPRGRHVVLAKFAGGGPTVTN
Peptide 2 (p60.1_406)	EEGIVPGGGASLIHQARKALTELRASL
Peptide 3 (p60.1_433)	TGDEVLGVDVFSEALAAPLFWIAANAGL
Peptide 4 (p60.1_461)	DGSV/NKVSELPAGHGLNVNTLSYGDLAAD
Peptide 6 (p60.1_515)	LTTETVVVDKPAKAEDHDHHHGHAH

10

Cpn60.1 batch used in these experiments: Cpn60.1 1_04-03/1.

We have investigated the effect of these peptides in a culture of spleen cells.

Spleens were collected from C57Bl/6 mice or TLR4 and TLR2 KO mice. The

15 organs were macerated in sterile conditions and cell suspension passed through

a 70 μ m cell strainer. Red blood cells were removed by osmotic shock with sterile water. The cells remained were washed and plated at 10⁶/well for IL-12 measurements. Cells were incubated with different concentrations of the peptides or chaperonin 60.1 (0.001-30 μ g/ml). Supernatants were collected 24h later and
5 kept at -20°C. IL-12 was measured by conventional ELISA assay.

Our experimental observations demonstrated that Cpn60.1 and all peptides induce IL-12 release in a splenocyte culture Peptide 4 is more effective than Cpn60.1 at lower concentrations (0.001 - 0.1 μ g/ml). However, at a higher
10 concentration (0.1 - 30 μ g/ml) this peptide showed a reduced effect in comparison to Cpn60.1. Peptide 6 has a similar effect at higher concentrations in comparison to Cpn60 but has a less potent effect at lower concentrations. (Figure 8). All cultures were performed in the presence of polymixin B to rule out any effect of LPS contamination on the functional responses that were measured.
15

We further examined the role of toll receptors (TLR) in the response of spleen cells to these peptide sequences. Spleen cells collected from TLR4 KO mice were significantly refractory in their ability to produce IL-12 in response to chaperonin 60.1 and its peptides when compared to their wild type counterpart
20 C57bl/6 mice. Spleen cells from TLR2 KO mice were also refractory in their ability to produce IL-12 in response to the chaperonin and its peptides.

This *in vitro* study shows biological activity of these peptide fragments is mediated by the activation of TLR2 and TLR4 (Figure 9).
25

Example 4 - The effect of chaperonin peptides *in vivo*

We next investigated the effect of low concentrations of Cpn60.1 and Cpn60.1-peptide 4 on allergic airways inflammation in light of the results obtained from the
30 in vitro studies described earlier.

In order to perform these experiments we have slightly modified our protocol of immunization. Allergic inflammation in the lung is induced by 2 intra-nasal instillations of 10 μ g of ovalbumin (OVA) in 100 μ g of alum with 7 days interval
35 between them. Control animals receive alum only. On day 14, all animals are

exposed to an aerosol of OVA for 25 minutes, once a day for 3 consecutive days. All measurements are performed 24h after the last antigen challenge.

We have shown that intra-nasal administration of Cpn60.1 (1 μ g) significantly
5 inhibited the total number of cells recruited to the lungs following acute antigen challenge (Figure 10). The effect of Cpn60.1 and peptide 4 on the eosinophil recruitment to the airways was more profound (Figure 11). Both low dose Cpn60.1 (0.1 and 1 μ g) and peptide 4 (0.005 μ g) caused a significant reduction in the recruitment of eosinophils which was not caused by an interference with the
10 production of IL-5 from inflammatory cells (Figure 12). Interestingly, low dose of peptide 4 affected total IgE production in this allergic model (Figure 13).

Example 5 - Cpn60.1 in models of pain

15 The effect of Cpn60.1 has been investigated in 2 models of pain, Complete Freund's Adjuvant (CFA)-induced hyperalgesia and Ultra Violet Burn-induced hyperalgesia. Mechanical hyperalgesia was measured using Von Frey filaments applied with increasing force to the hind paw. Thermal hyperalgesia was
20 measured using the time taken to withdraw the hind paw from a heat source. Cpn60.1 (50 & 500 μ g/kg) was chronically administered to male Wistar rats (200g) subcutaneously for 7 days. Every alternate day behavioural responses to mechanical and thermal allodynia were recorded. After baseline recordings, CFA was injected in to the hind paw to induce hyperalgesia and behavioural tests were
25 performed. Neither dose of Cpn60.1 reduced CFA-induced hyperalgesia compared to the control, ibuprofen (100mg/kg) (Figures 14 and 15). Another model of hyperalgesia was tested, this time using UV burn to induce allodynia. Again, Cpn60.1 had little effect at inhibiting hyperalgesia compared to the group treated with ibuprofen (Figures 16 and 17).

30

Example 6 - In vitro studies on human inflammatory cells

We have established a human monocyte assay to compare the efficacy of
35 Cpn60.1 and various peptide sequences of this protein. Human monocytes were obtained by density-dependent centrifugation from peripheral venus blood from

healthy volunteers. Monocytes were then isolated and purified with cells adjusted to a density of 2×10^6 cells/ml which were incubated for 1 hour 30 minutes. The plates were then washed twice with Hanks solution. 0.9ml of RPMI medium was then added to each well followed by polymyxin-B (5 μ g/ml). 30 minutes later, 5 0.1ml of Cpn at 0.0001-1000 ng/ml or peptides were added to the wells. Cells were then incubated at 37°C, 5% CO₂ for 1 hour. The medium was removed and cells washed. 0.9ml of medium was added to each well followed by 0.1ml of LPS (1ng/ml) and left to incubate for 24 hours. Supernatant was taken from each well and frozen for Enzyme Linked Immunosorbent Assay (ELISA).

10

We have demonstrated that Cpn60.1 alone, is able to stimulate human monocytes to induce TNF-alpha secretion but when added to an already established inflammatory stimulus (*i.e.* in the presence of LPS), Cpn60.1 inhibited TNF-alpha secretion at low doses (1ng/ml) (Figure 18). In contrast, Cpn10, failed 15 to inhibit TNF-alpha secretion from human monocytes (Figure 20). However, the protein appears to have a degree of LPS contamination and in the presence of polymyxin B, this contamination is reduced (Figure 19). This potential confounding with LPS contamination is avoided when using the peptide sequences of Cpn60.1. The peptides also appeared to inhibit TNF-alpha 20 secretion at low concentrations (Figure 21).

Example 7 - Cpn60.1 in models of non-allergic inflammation

25 Because of the inhibitory effect in human inflammatory cells, we investigated whether Cpn60.1 is able to inhibit neutrophil recruitment in an *in vivo* system. To support this further, Riffo-Vasquez *et al.* have recently showed that *M. tuberculosis* chaperones can suppress eosinophil recruitment and bronchial hyper-responsiveness in a murine model of allergic inflammation (Riffo-Vasquez 30 Y, Spina D, Page C *et al.* Effect of Mycobacterium tuberculosis chaperonins on bronchial eosinophilia and hyper-responsiveness in a murine model of allergic inflammation. *Clin. Exp Allergy*, 2004; 34(5); 712-719).

Female Balb/c mice were pre-treated intranasally with Cpn60.1 (1 μ g/ml) for 3 35 days in the absence or following pre-treatment with polymyxin B (5 μ g/ml) to rule out any effect of LPS contamination. 30 minutes after the last dose of Cpn60.1,

mice were treated with LPS (1 μ g/ml). Neutrophil influx and TNF-alpha release in the lungs were determined by bronchoalveolar lavage 24 hours later. LPS induced a dose dependent increase in neutrophilia compared to control (Figure 22). Interestingly, the group pre-treated with Cpn60.1 showed suppression in 5 neutrophilia but TNF-alpha secretion was not significantly attenuated (Figure 24). The treatment of mice with polymyxin B made no difference to the ability of Cpn60.1 to suppress neutrophil recruitment indicating that this effect cannot be explained by contamination with LPS. No neutrophil recruitment was observed in mice treated with Cpn60.1 alone further enabling that any contamination with LPS 10 failed to cause neutrophilia (Figure 23).

Example 8 – Exemplary pharmaceutical formulations

15 Whilst it is possible for a molecule of the invention to be administered alone, it is preferable to present it as a pharmaceutical formulation, together with one or more acceptable carriers. The carrier(s) must be “acceptable” in the sense of being compatible with the agent of the invention and not deleterious to the recipients thereof. Typically, the carriers will be water or saline which will be sterile and 20 pyrogen-free.

The following examples illustrate medicaments and pharmaceutical compositions according to the invention in which the active ingredient is a molecule of the invention.

25 Preferably, the molecule of the invention is provided in an amount from 10 μ g to 500mg. It will be appreciated that the following exemplary medicaments and pharmaceutical compositions may be prepared containing an amount of the molecule of the invention from 10 μ g to 500mg. For example, the molecule of the 30 invention may be present in a 10th or 100th or 200th or 500th of the amount shown in the following exemplary medicaments and pharmaceutical compositions with the amounts of the remaining ingredients changed accordingly.

Example A: Tablet

Active ingredient	1 mg
Lactose	200 mg
5 Starch	50 mg
Polyvinylpyrrolidone	5 mg
Magnesium stearate	4 mg

Tablets are prepared from the foregoing ingredients by wet granulation followed by

10 compression.

Example B: Ophthalmic Solution

15 Active ingredient	1 mg
Sodium chloride, analytical grade	0.9 g
Thiomersal	0.001 g
Purified water to	100 ml
pH adjusted to	7.5

20

Example C: Tablet Formulations

The following formulations A and B are prepared by wet granulation of the
25 ingredients with a solution of povidone, followed by addition of magnesium stearate
and compression.

Formulation A

		<u>mg/tablet</u>	<u>mg/tablet</u>
30 (a) Active ingredient		1	1
(b) Lactose B.P.		210	26
(c) Povidone B.P.		15	9
(d) Sodium Starch Glycolate		20	12
(e) Magnesium Stearate		5	3

35

	251	51
--	-----	----

Formulation B

		<u>mg/tablet</u>	<u>mg/tablet</u>
5	(a) Active ingredient	1	1
	(b) Lactose	150	-
	(c) Avicel PH 101®	60	26
	(d) Povidone B.P.	15	9
	(e) Sodium Starch Glycolate	20	12
10	(f) Magnesium Stearate	5	3
		—	—
		251	51

Formulation C

		<u>mg/tablet</u>
15	Active ingredient	1
	Lactose	200
	Starch	50
	Povidone	5
20	Magnesium stearate	4
		—
		260

The following formulations, D and E, are prepared by direct compression of the
 admixed ingredients. The lactose used in formulation E is of the direction
 compression type.

Formulation D

		<u>mg/capsule</u>
30	Active Ingredient	1
	Pregelatinised Starch NF15	150
		—
		151

Formulation E

	<u>mg/capsule</u>
Active Ingredient	1
Lactose	150
5 Avicel®	100
	—
	251

10 Formulation F (Controlled Release Formulation)

The formulation is prepared by wet granulation of the ingredients (below) with a solution of povidone followed by the addition of magnesium stearate and compression.

	<u>mg/tablet</u>
(a) Active Ingredient	1
(b) Hydroxypropylmethylcellulose (Methocel K4M Premium)®	112
(c) Lactose B.P.	53
20 (d) Povidone B.P.C.	28
(e) Magnesium Stearate	7
	—
	201

25 Drug release takes place over a period of about 6-8 hours and was complete after 12 hours.

Example D: Capsule Formulations30 Formulation A

A capsule formulation is prepared by admixing the ingredients of Formulation D in Example C above and filling into a two-part hard gelatin capsule. Formulation B (infra) is prepared in a similar manner.

Formulation B

	<u>mg/capsule</u>
(a) Active ingredient	1
(b) Lactose B.P.	143
5 (c) Sodium Starch Glycolate	25
(d) Magnesium Stearate	2
	—
	171

10 Formulation C

	<u>mg/capsule</u>
(a) Active ingredient	1
(b) Macrogol 4000 BP	350
	—
	351

Capsules are prepared by melting the Macrogol 4000 BP, dispersing the active ingredient in the melt and filling the melt into a two-part hard gelatin capsule.

	<u>mg/capsule</u>
20 Active ingredient	1
Lecithin	100
Arachis Oil	100
	—
	201

Capsules are prepared by dispersing the active ingredient in the lecithin and arachis oil and filling the dispersion into soft, elastic gelatin capsules.

30 Formulation E (Controlled Release Capsule)

The following controlled release capsule formulation is prepared by extruding ingredients a, b, and c using an extruder, followed by spheronisation of the extrudate and drying. The dried pellets are then coated with release-controlling membrane (d) and filled into a two-piece, hard gelatin capsule.

	<u>mg/capsule</u>
(a) Active ingredient	1
(b) Microcrystalline Cellulose	125
(c) Lactose BP	125
5 (d) Ethyl Cellulose	13
	—
	264

Example E: Injectable Formulation

10

Active ingredient 1mg
Sterile, pyrogen free phosphate buffer (pH7.0) to 10 ml

15

The active ingredient is dissolved in most of the phosphate buffer (35-40°C), then made up to volume and filtered through a sterile micropore filter into a sterile 10 ml amber glass vial (type 1) and sealed with sterile closures and overseals.

Example F: Intramuscular injection

20

Active ingredient 1mg
Benzyl Alcohol 0.10 g
Glucofurol 75® 1.45 g
Water for Injection q.s. to 3.00 ml

25

The active ingredient is dissolved in the glycofurol. The benzyl alcohol is then added and dissolved, and water added to 3 ml. The mixture is then filtered through a sterile micropore filter and sealed in sterile 3 ml glass vials (type 1).

30

Example G: Syrup Suspension

Active ingredient	1mg
Sorbitol Solution	1.5000 g
Glycerol	2.0000 g
Dispersible Cellulose	0.0750 g
Sodium Benzoate	0.0050 g
Flavour, Peach 17.42.3169	0.0125 ml
Purified Water q.s. to	5.0000 ml

10

The sodium benzoate is dissolved in a portion of the purified water and the sorbitol solution added. The active ingredient is added and dispersed. In the glycerol is dispersed the thickener (dispersible cellulose). The two dispersions are mixed and made up to the required volume with the purified water. Further thickening is achieved as required by extra shearing of the suspension.

15

Example H: Suppositorymg/suppository

20	Active ingredient (63 µm)*	1
	Hard Fat, BP (Witepsol H15 - Dynamit Nobel)	1770
		—
		1771

25 *The active ingredient is used as a powder wherein at least 90% of the particles are of 63 µm diameter or less.

One fifth of the Witepsol H15 is melted in a steam-jacketed pan at 45°C maximum. The active ingredient is sifted through a 200 µm sieve and added to the molten base 30 with mixing, using a silverson fitted with a cutting head, until a smooth dispersion is achieved. Maintaining the mixture at 45°C, the remaining Witepsol H15 is added to the suspension and stirred to ensure a homogenous mix. The entire suspension is passed through a 250 µm stainless steel screen and, with continuous stirring, is allowed to cool to 40°C. At a temperature of 38°C to 40°C 2.02 g of the mixture is 35 filled into suitable plastic moulds. The suppositories are allowed to cool to room temperature.

Example I: Pessaries

	<u>mg/pessary</u>
Active ingredient	1
Anhydrate Dextrose	380
5 Potato Starch	363
Magnesium Stearate	7
	—
	751

- 10 The above ingredients are mixed directly and pessaries prepared by direct compression of the resulting mixture.

Example 9 – Treatment of a non-cancerous disorder using a molecule of the

15 invention

A patient with arthritis is administered 1mg of an agent of the invention per day intramuscularly or a depot preparation delivering this dose according to the methods of the invention.

20

Example 10 - Methods of pain relief

The molecules of the invention will provide effective pain relief in the following

25 incidences of pain: backache, headache, toothache, earache, Arthritis, Gout, soft tissue trauma, ligament/tendon traumatic damage, broken bones, Cancer, post operative pain, menstrual pain, obstetric pain, renal tract pain, visceral pain, burns, abscesses and other infections.

30 The suggested treatment route and regimen for the treatment of any of these conditions is the administration of 0.1mg to 1 gram once every 12 hours by inhalation delivered via an inhaler. However the skilled person would know that the most appropriate treatment regime would be dependent on the individual and the severity of the pain being felt.

35

Claims

1. An isolated or recombinant peptide molecule comprising or consisting of a polypeptide sequence selected from the group:

5

- (i) MSKLIEYDETARRAMEVGMDKLADTVRVT;
- (ii) LGPRGRHVVLAQAFGGPTVTN;
- (iii) DGTVAREIELEDPFEDLGAQLVKSATKTNDV;
- (iv) AGDGTTTATILAQALIKGGLRLVAAGVN;
- 10 (v) PIALGVGIGKAADAVSEALLASATP;
- (vi) EEEGIVPGGGASLIHQARKALTELRASL;
- (vii) TGDEVLGVDFVSEALAAPLFWIAANAGL;
- (viii) DGSVVVNVKSELPGAGHGLNVNTLSYGDLAAD;
- (ix) GVIDPVKVTRSAVLNASSVARMVLTETVVV;
- 15 (x) LTTETVVVDKPAKAEDHDHHHGHAH;

- (xi) a polypeptide sequence which has more than 66% or 70% or 75% or 80% or 85% or 90% or 95% identity to a polypeptide sequence defined in any of (i) to (x) and has a function equivalent to a polypeptide sequence defined in any of (i) to (x); and

- (xii) a fragment of a polypeptide sequence defined in any of (i) to (xi) which has a function equivalent to a polypeptide sequence defined in any of (i) to (xi).

25

2. An isolated or recombinant nucleic acid molecule comprising or consisting of a polynucleotide sequence selected from the group:

30

- (a) a polynucleotide sequence which encodes a polypeptide sequence selected from the group consisting of:
 - (i) MSKLIEYDETARRAMEVGMDKLADTVRVT;
 - (ii) LGPRGRHVVLAQAFGGPTVTN;
 - (iii) DGTVAREIELEDPFEDLGAQLVKSATKTNDV;
 - 35 (iv) AGDGTTTATILAQALIKGGLRLVAAGVN;
 - (v) PIALGVGIGKAADAVSEALLASATP;

- 5 (vi) EEGIVPGGGASLIHQARKALTELRASL;
(vii) TGDEVLGVDFVSEALAAPLFWIAANAGL;
(viii) DGSVVVNKVSELPAGHGLNVNTLSYGDLAAD;
(ix) GVIDPVKVTRSAVLNASSVARMVLTTETVVV;
(x) LTTETVVVDKPAKAEDHDHHGHAH;

10 (b) a polynucleotide sequence which has more than 66% or 70% or 75% or 80% or 85% or 90% or 95% identity to a polynucleotide sequence defined in (a); or a polynucleotide sequence which hybridizes to a polynucleotide sequence defined in (a) under conditions of 2xSSC, 65°C which encodes a polypeptide sequence having a function equivalent to a polypeptide sequence defined in any of (i) to (x); and

15 (c) a fragment of a polynucleotide sequence defined in (a) or (b) which encodes a polypeptide sequence having a function equivalent to a polypeptide sequence defined in any of (i) to (x).

20 3. A peptide molecule as defined in Claim 1 for use in medicine.

25 4. A nucleic acid molecule as defined in Claim 2 for use in medicine.

30 5. A peptide molecule as defined in Claim 1 for use in preventing and/or treating a non-cancerous condition or a cancerous condition.

35 6. A nucleic acid molecule as defined in Claim 2 for use in preventing and/or treating a non-cancerous condition or a cancerous condition.

7. Use of a peptide molecule as defined in Claim 1 or a nucleic acid molecule as defined in Claim 2 in the manufacture of a medicament for preventing and/or treating a non-cancerous condition or a cancerous condition.

8. A pharmaceutical composition comprising or consisting of a peptide molecule as defined in Claim 1, and a pharmaceutically-acceptable excipient.

9. A pharmaceutical composition comprising or consisting of a nucleic acid molecule as defined in Claim 2, and a pharmaceutically-acceptable excipient.

5 10. The pharmaceutical composition according to Claim 8 or 9 which is for use in preventing or treating a non-cancerous condition or a cancerous condition.

10 11. A method of preventing and/or treating a non-cancerous condition or a cancerous condition in a patient comprising the step of administering to a patient in need thereof an effective amount of a peptide molecule as defined in Claim 1 or a pharmaceutical composition as defined in Claim 8 or 10.

15 12. A method of preventing and/or treating a non-cancerous condition or a cancerous condition in a patient comprising the step of administering to a patient in need thereof an effective amount of a nucleic acid molecule as defined in Claim 2 or a pharmaceutical composition as defined in Claim 9 or 10.

20 13. A peptide molecule according to Claim 5 or a nucleic acid molecule according to Claim 6 or a use according to Claim 7 or a pharmaceutical composition according to Claim 10 or a method according to Claim 11 or 25 12 wherein the non-cancerous condition is selected from the group comprising or consisting of: autoimmune disorders, such as haemolytic anaemia, thrombocytopenia, thyroiditis, pernicious anaemia, Addison's disease, autoimmune diabetes, myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus, atherosclerosis, and autoimmune encephalitis; allergic conditions such as eczema, dermatitis, allergic rhinitis, allergic conjunctivitis; allergic airways diseases; hyper-eosinophilic syndrome; contact dermatitis, food allergy; and respiratory diseases characterized by eosinophilic airway inflammation and airway hyper-responsiveness, such as allergic asthma, intrinsic asthma, allergic bronchopulmonary aspergillosis, eosinophilic pneumonia, allergic 30 35 bronchitis bronchiectasis, occupational asthma, reactive airway disease

syndrome, interstitial lung disease, hyper-eosinophilic syndrome, parasitic lung disease.

14. A peptide molecule according to Claim 5 or a nucleic acid molecule

5 according to Claim 6 or a use according to Claim 7 or a pharmaceutical composition according to Claim 10 or a method according to Claim 11 or 12 wherein the non-cancerous condition is asthma.

15. A peptide molecule according to Claim 5 or a nucleic acid molecule

10 according to Claim 6 or a use according to Claim 7 or a pharmaceutical composition according to Claim 10 or a method according to Claim 11 or 12 wherein the non-cancerous condition is arthritis.

16. A peptide molecule according to Claim 5 or a nucleic acid molecule

15 according to Claim 6 or a use according to Claim 7 or a pharmaceutical composition according to Claim 10 or a method according to Claim 11 or 20 12 wherein the non-cancerous condition is selected from the group comprising or consisting of: solid phase tumors/malignancies, locally advanced tumors, human soft tissue sarcomas, metastatic cancer, including lymphatic metastases, blood cell malignancies including multiple myeloma, acute and chronic leukemias, and lymphomas, head and neck cancers including mouth cancer, larynx cancer and thyroid cancer, lung cancers including small cell carcinoma and non-small cell cancers, breast cancers including small cell carcinoma and ductal carcinoma, 25 gastrointestinal cancers including esophageal cancer, stomach cancer, colon cancer, colorectal cancer and polyps associated with colorectal neoplasia, pancreatic cancers, liver cancer, urologic cancers including bladder cancer and prostate cancer, malignancies of the female genital tract including ovarian carcinoma, uterine (including endometrial) cancers, 30 and solid tumor in the ovarian follicle, kidney cancers including renal cell carcinoma, brain cancers including intrinsic brain tumors, neuroblastoma, astrocytic brain tumors, gliomas, metastatic tumor cell invasion in the central nervous system, bone cancers including osteomas, skin cancers including malignant melanoma, tumor progression of human skin keratinocytes, squamous cell carcinoma, basal cell carcinoma, 35 hemangiopericytoma and Karposi's sarcoma

17. A peptide molecule as defined in Claim 1 for use in the relief of pain.
18. A nucleic acid molecule as defined in Claim 2 for use in the relief of pain.
- 5 19. The pharmaceutical composition according to Claim 8 or 9 which is for use in the relief of pain.
- 10 20. Use of a peptide molecule as defined in Claim 1 or a nucleic acid molecule as defined in Claim 2 in the manufacture of a medicament for the relief of pain.
- 15 21. The use according to Claim 20 wherein the medicament further comprises at least one additive for assisting or augmenting the action of the peptide molecule or nucleic acid molecule.
- 20 22. The use according to Claim 21 wherein the additive is selected from at least one of paracetamol, aspirin, ibuprofen, other non-steroidal anti-inflammatory drugs (NSAIDS), cylooxygenase-2-selective inhibitors (CSIs), opiates.
- 25 23. The use according to any of Claims 20 to 22 wherein the medicament provides prolonged or sustained pain relief.
24. The use according to any of Claims 20 to 23 wherein the daily dosage level will be from 0.0001 to 100,000 mg, administered in single or divided doses.
- 30 25. The use according to Claim 24 wherein the daily dosage level is 0.0001 to 1000 mg.
26. The use according to Claim 24 or 25 wherein the time between dose administration to the patient is between six and twelve hours.

27. The use according to Claim 24 or 25 wherein the time between dose administration to the patient is between nine and twelve hours after the previous dose
- 5 28. The use according to Claim 24 or 25 wherein the time between dose administration to the patient is between twelve hours and twelve days.
29. The use according to Claim 24 or 25 wherein the time between dose administration to the patient is between twelve days and six months.
- 10 30. The use according to any of Claims 20 to 29 wherein the medicament is used to relieve pain in a human or animal patient.
- 15 31. The pharmaceutical composition according to any one of Claims 8 to 10 or 18 or the medicament as defined in any of Claims 7 or 20 to 30 wherein the pharmaceutical composition or medicament is formulated to permit administration by at least one route selected from the group comprising or consisting of: intranasal; oral; parenteral; topical; ophthalmic; suppository; pessary; or inhalation routes.
- 20 32. A peptide molecule according to Claim 16 or a nucleic acid molecule according to Claim 17 or a pharmaceutical composition according to Claim 29 or a use as defined in any of Claims 7 or 20 to 30 wherein pain is selected from the group comprising or consisting of: backache; headache; toothache; earache; arthritis; gout; soft tissue trauma; ligament and/or tendon traumatic damage; broken bones; cancer; post-operative pain; menstrual pain; obstetric pain; renal tract pain; visceral pain; burns; abscesses; and other infections.
- 25 33. A method of relieving pain in a patient comprising the step of administering to a patient in need thereof an effective amount of a peptide molecule as defined in Claim 1 or a pharmaceutical composition according to any one of Claims 8 to 10, 20 or 31.
- 30 34. A method of relieving pain in a patient comprising the step of administering to a patient in need thereof an effective amount of a nucleic

acid molecule as defined in Claim 2 or a pharmaceutical composition according to any one of Claims 8 to 10, 20 or 31.

35. Use of a peptide molecule as defined in Claim 1 or a nucleic acid molecule
5 as defined in Claim 2 as an adjuvant.

36. An adjuvant system comprising (i) a peptide molecule as defined in Claim 1 or a nucleic acid molecule as defined in Claim 2 and (ii) an antigen.

10 37. The adjuvant system according to Claim 36 wherein the antigen is selected from the group comprising or consisting of: anthrax antigen; cholera antigen; diphtheria antigen; haemophilus influenza b (Hib) antigen; hepatitis A antigen; hepatitis B antigen; influenza antigen; Japanese encephalitis antigen; measles, mumps and rubella (MMR) antigen; meningococcal antigen; pertussis antigen; pneumococcal antigen; poliomyelitis antigen; rabies antigen; rubella antigen; smallpox and/or vaccinia antigen; tetanus antigen; tick-borne encephalitis antigen; tuberculosis antigen; typhoid antigen; varicella/herpes zoster antigen; yellow fever antigen; and veterinary vaccine antigen.

20 38. A method of stimulating cytokine production in a cell comprising the step of administering a peptide molecule as defined in Claim 1 or a nucleic acid molecule as defined in Claim 2.

25 39. The method according to Claim 38 wherein cytokine production is increased at least 10-fold relative to normal levels.

40. The method according to Claim 38 or 39 wherein the cytokine is selected from the group comprising or consisting of: IL-1 β ; IL-2; IL-6; IL-8; IL-10; IL-12; TNF- α ; Interferon- γ ; GM-CSF.

30 41. A method of assessing the presence and/or amount in a sample of a peptide molecule according to Claim 1 or a nucleic acid molecule according to Claim 2 comprising or consisting of the steps of:

35 i) providing a test sample;

- ii) contacting the test sample with a cell;
- iii) measuring and/or detecting the level of production of one or more cytokine by the cell;
- iv) comparing the level of production of one or more cytokine in (iii) with the level of production of the one or more cytokine in a control sample

5 wherein a higher level of production of one or more cytokine induced by
10 the test sample compared to the control sample indicates the presence
and/or amount in the test sample of a peptide molecule according to Claim
1 or a nucleic acid molecule according to Claim 2.

- 15
- 42. A peptide molecule or a nucleic acid molecule substantially as described herein with reference to the accompanying description and drawings.
 - 43. A pharmaceutical composition, use or method substantially as described herein with reference to the accompanying description and drawings.

20


Figure 1


Figure 2


Figure 3

Figure 4






Figure 5


Figure 6


Figure 7

Figure 8




Figure 9




Figure 10





Figure 11


Figure 12

Figure 13





Figure 14


Figure 15


Figure 16


Figure 17

Figure 18





Figure 19


Figure 20

Figure 21





Figure 22


Figure 23


Figure 24

Figure 25
Peptides covering the equatorial (black) domain of *M. tuberculosis* Cpn60.1




Figure 25 continued

	Peptide	Position (in respect of full-length protein)	Comment
1	MSKLIYEDETARRAMEVGMDKLADTVRVT	1-29	First 30 amino acids of the protein. Contains half a β -sheet and a alpha-helix. Highly surface exposed
2	LGPRGRHIVLAKAFAFGGPTV/TN	30-50	Comprises a β -sheet in the structure. Highly surface exposed
3	DGVTVAREIELEDPFEDLGAQLV/KSVATKTNDV	51-83	Comprises of 2 alpha-helices within the structure. Exposed to the "inner side of a putative oligomeric structure (unknown whether oligomeric structure exists)
4	AGDGTATTILAGACALIKGGRLVAAGWN	84-110	Comprises of a single alpha-helix. Only partly exposed. Runs through the centre of the domain
5	PIALGVIGIGKAADAVSEALLASAATP	111-136	Comprises of a single alpha-helix. Highly surface exposed
6	EEGIVPGGGASLIHQARKALTTELRAISL	406-432	Comprises of one half of a β -sheet, an alpha helix and an linker region. Partly (β -sheet) buried in the structure
7	TGDEVLGVDVFSEALAAPLFW/AAAGL	433-460	Comprises of two alpha-helices. Highly surface exposed. This area is one of the regions with high dissimilarity with Cpn60.2
8	DGSVVVNKV/SELPAHGHLNVNTLSY/GDLAAD	461-491	Comprises of an alpha helix, a β -sheet and another alpha helix. Highly surface exposed
9	GVIDPVKVTRSAVLNAASSVARMVLTETVVV	492-522	Highly surface exposed towards the inner face of a putative oligomeric structure. Contains one half of a β sheet.
10	LTETTVVVDKPKAKAEDHDHHHGHAH	515-539	Last 25 aa. Not visible in the putative structure. Seems to be flexible and could therefore not be resolved in the <i>E. coli</i> / structure. This is another area of high dissimilarity with Cpn60.2

Figure 25 continued

Examples of peptides and purity of manufacture

Sequence	Name	Code	Purity	List number
LGPRGRHVVLAKAFGGPTVTN	p60.1_30	M1429-A1	96 %	2
EEGIVPGGGASLIHQARKALTELRASL	p60.1_406	M1429-A2	99 %	6
TGDEVLGVDVFSEALAAPLFWIAANAGL	p60.1_433	M1429-A3	96 %	7
DGSVVAVNKVSELPAHGGLNVNTLSYGDLAAD	p60.1_461	M1429-A4	96 %	8
GVIDPVKVTRSAVLNAASSVARMVLTTETVV	p60.1_492	M1429_A5		9
LTTETVVWDKPAKAEDHDHHHGHAH	p60.1_515	M1429-A6	98.5 %	10